Details
Title
Author Correction: Propensity of selecting mutant parasites for the antimalarial drug cabamiquine
Author
Stadler, Eva 1
; Maiga, Mohamed 2
; Friedrich, Lukas 3 ; Thathy, Vandana 4 ; Demarta-Gatsi, Claudia 5
; Dara, Antoine 2
; Sogore, Fanta 2 ; Striepen, Josefine 6
; Oeuvray, Claude 7 ; Djimdé, Abdoulaye A. 2
; Lee, Marcus C. S. 8
; Dembélé, Laurent 2 ; Fidock, David A. 9
; Khoury, David S. 1
; Spangenberg, Thomas 10
1 UNSW Sydney, The Kirby Institute, Kensington, Australia (GRID:grid.1005.4) (ISNI:0000 0004 4902 0432)
2 Université des Sciences, des Techniques et des Technologies de Bamako (USTTB), Faculté de Pharmacie, Malaria Research and Training Center (MRTC), Point G, Bamako, Mali (GRID:grid.461088.3) (ISNI:0000 0004 0567 336X)
3 Medicinal Chemistry & Drug Design Global Research & Development, Discovery Technologies, Merck Healthcare, Darmstadt, Germany (GRID:grid.39009.33) (ISNI:0000 0001 0672 7022)
4 Columbia University Irving Medical Center, Department of Microbiology and Immunology, New York, USA (GRID:grid.239585.0) (ISNI:0000 0001 2285 2675); Columbia University Irving Medical Center, Center for Malaria Therapeutics and Antimicrobial Resistance, New York, USA (GRID:grid.239585.0) (ISNI:0000 0001 2285 2675)
5 Global Health Institute of Merck, Eysins, Switzerland (GRID:grid.239585.0)
6 Columbia University Irving Medical Center, Department of Microbiology and Immunology, New York, USA (GRID:grid.239585.0) (ISNI:0000 0001 2285 2675); Weill Cornell Medical College, New York, USA (GRID:grid.5386.8) (ISNI:000000041936877X)
7 Global Health Institute of Merck, Eysins, Switzerland (GRID:grid.5386.8)
8 Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton, UK (GRID:grid.10306.34) (ISNI:0000 0004 0606 5382); School of Life Sciences, University of Dundee, Biological Chemistry and Drug Discovery, Scotland, UK (GRID:grid.8241.f) (ISNI:0000 0004 0397 2876)
9 Columbia University Irving Medical Center, Department of Microbiology and Immunology, New York, USA (GRID:grid.239585.0) (ISNI:0000 0001 2285 2675); Columbia University Irving Medical Center, Center for Malaria Therapeutics and Antimicrobial Resistance, New York, USA (GRID:grid.239585.0) (ISNI:0000 0001 2285 2675); Columbia University Irving Medical Center, Division of Infectious Diseases, Department of Medicine, New York, USA (GRID:grid.239585.0) (ISNI:0000 0001 2285 2675)
10 Global Health Institute of Merck, Eysins, Switzerland (GRID:grid.1005.4)
; Maiga, Mohamed 2
; Friedrich, Lukas 3 ; Thathy, Vandana 4 ; Demarta-Gatsi, Claudia 5
; Dara, Antoine 2
; Sogore, Fanta 2 ; Striepen, Josefine 6
; Oeuvray, Claude 7 ; Djimdé, Abdoulaye A. 2
; Lee, Marcus C. S. 8
; Dembélé, Laurent 2 ; Fidock, David A. 9
; Khoury, David S. 1
; Spangenberg, Thomas 10
1 UNSW Sydney, The Kirby Institute, Kensington, Australia (GRID:grid.1005.4) (ISNI:0000 0004 4902 0432)
2 Université des Sciences, des Techniques et des Technologies de Bamako (USTTB), Faculté de Pharmacie, Malaria Research and Training Center (MRTC), Point G, Bamako, Mali (GRID:grid.461088.3) (ISNI:0000 0004 0567 336X)
3 Medicinal Chemistry & Drug Design Global Research & Development, Discovery Technologies, Merck Healthcare, Darmstadt, Germany (GRID:grid.39009.33) (ISNI:0000 0001 0672 7022)
4 Columbia University Irving Medical Center, Department of Microbiology and Immunology, New York, USA (GRID:grid.239585.0) (ISNI:0000 0001 2285 2675); Columbia University Irving Medical Center, Center for Malaria Therapeutics and Antimicrobial Resistance, New York, USA (GRID:grid.239585.0) (ISNI:0000 0001 2285 2675)
5 Global Health Institute of Merck, Eysins, Switzerland (GRID:grid.239585.0)
6 Columbia University Irving Medical Center, Department of Microbiology and Immunology, New York, USA (GRID:grid.239585.0) (ISNI:0000 0001 2285 2675); Weill Cornell Medical College, New York, USA (GRID:grid.5386.8) (ISNI:000000041936877X)
7 Global Health Institute of Merck, Eysins, Switzerland (GRID:grid.5386.8)
8 Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton, UK (GRID:grid.10306.34) (ISNI:0000 0004 0606 5382); School of Life Sciences, University of Dundee, Biological Chemistry and Drug Discovery, Scotland, UK (GRID:grid.8241.f) (ISNI:0000 0004 0397 2876)
9 Columbia University Irving Medical Center, Department of Microbiology and Immunology, New York, USA (GRID:grid.239585.0) (ISNI:0000 0001 2285 2675); Columbia University Irving Medical Center, Center for Malaria Therapeutics and Antimicrobial Resistance, New York, USA (GRID:grid.239585.0) (ISNI:0000 0001 2285 2675); Columbia University Irving Medical Center, Division of Infectious Diseases, Department of Medicine, New York, USA (GRID:grid.239585.0) (ISNI:0000 0001 2285 2675)
10 Global Health Institute of Merck, Eysins, Switzerland (GRID:grid.1005.4)
Pages
5447
Publication year
2023
Publication date
2023
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2861510292
Copyright
© The Author(s) 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.